Clinical Trial Update: Miltefosine to Treat Mucocutaneous Leishmaniasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of miltefosine for mucocutaneous leishmaniasis completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis
• Mucosal Leishmaniasis

Drugs mentioned

• Miltefosine (miltefosine)

Snippet

Sponsor: Knight Therapeutics (USA) Inc | Conditions: Mucosal Leishmaniasis, Cutaneous Leishmaniasis | Phase 2 | Status: COMPLETED | Results posted: 2020-09-30